Deals Of The Week: Roche/Cellular Dynamics, Pfizer/Philogen, Takeda/Amylin
Executive Summary
Epizyme/Celgene, Amylin/BMS/AstraZeneca and Foundation Medicine garner readers’ huzzahs in our 2012 Deals of the Year poll. Plus Roche, Pfizer and Sanofi Pasteur start off 2013’s deal-making.
You may also be interested in...
Celgene Dips Into The Antibody Well Once More, Partners With Sutro
Celgene Corp. has deepened its investment in antibody R&D, striking a collaboration with Sutro Biopharma to design and develop next-gen antibodies and to manufacture a proprietary Celgene candidate. Sutro gets cash, biobucks, and hi-profile validation of its multi-faceted non-cell antibody platform.
With Bristol/AstraZeneca In Driver’s Seat, GLP-1 Race Takes A Turn
Bristol-Myers and AstraZeneca’s acquisition of Amylin as part of a 50-50 collaboration brings a big new player into the fast-growing GLP-1 class, which is emerging as a key component of treatment in the large, but highly competitive Type 2 diabetes market.
Top Seven Pink Sheet Infographics Of 2023
A visual perspective on key regulatory topics in 2023, from clinical trial diversity to product approval trends and Medicare drug price negotiation.